CINCINNATI – A study led by specialists at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute affirms the benefits and safety of aggressive, localized treatment for patients with a single brain metastasis.

The retrospective study of 72 patients, published in the May issue of the Journal of Neuro-Oncology, demonstrates that the implantation of radioactive seeds following the surgical removal of a single brain metastasis is as effective as the standard treatment of radiating the entire brain following surgery. Radiation seeds are titanium casings about the size of a grain of rice that are filled with low-level, I-125 radioactivity.

The standard treatment, known as whole-brain radiation therapy (WBRT), effectively kills microscopic and undetectable cancer cells not only around the tumor but also in other parts of the brain where they have not yet been detected with MRI scans. But it can cause long-term radiation toxicity and can result in cognitive problems in up to 10 percent of patients.

“The potential adverse affects of WBRT are of concern,” said Ronald Warnick, M.D., who is Director of the Brain Tumor Center, Chairman of the Mayfield Clinic, and the study’s principal investigator. “These include acute effects, such as fatigue and hair loss, but also delayed, cognitive effects, including memory loss and personality changes. These cognitive side effects can compromise the benefit that WBRT provides.”

The risk of cognitive impairment is especially undesirable because patients with a single brain metastasis can survive longer than one to two years.

In their ongoing quest to practice evidence-based medicine, Dr. Warnick and his team performed their study to discover whether the implantation of radiation seeds following the removal of a single brain metastasis is as effective as WBRT as a treatment for patients.

The study involved a retrospective review of 72 patients who were treated with surgery and radiation seeds without up-front radiation at the Brain Tumor Center at University Hospital from 1997 to 2007. The study builds on a previous UC study of localized treatment of a single metastasis.
Dr. Warnick and his team demonstrated that, with radiation seeds, they were able to safely maintain control of the tumor at the surgical site in more than 90 percent of cases, while eliminating the need for WBRT – with its associated side effects -- in all but five patients. “We initially feared that omitting WBRT would result in uncontrollable metastases elsewhere in the brain,” Dr. Warnick said. “However, these distant metastases were generally well controlled with surgery, stereotactic radiosurgery (the delivery of targeted beams of radiation), or WBRT.”

The new study, with the addition of more patients and longer followup, strengthens previous results and recommendations that the use of I-125 seeds is an effective alternative to WBRT.

Sixteen months following surgical removal of the metastatic tumor and the implantation of seeds, 67 study participants (93 percent) had no recurrence of the tumor at the surgical site. Five patients developed a recurrence at the tumor resection site, while 23 patients developed metastases in another part of the brain.

The Brain Tumor Center team used backup strategies to treat patients who experienced a local recurrence or distant metastases. Chief among those strategies was stereotactic radiosurgery, which involves the destruction of cancerous tissue with precisely targeted beams of radiation. Radiosurgery procedures were overseen by study co-investigator John Breneman, M.D., a radiation oncologist with the Brain Tumor Center and Professor of Radiation Oncology at UC.

“In the end, 93 percent of the patients we studied did not require whole brain radiation and therefore were not exposed to the risks of cognitive problems and the inevitable side effect of hair loss,” Dr. Warnick said.

Said Dr. Breneman: “This form of treatment is another incremental advance in the work being done to prolong the lives of patients with brain metastases while preserving their quality of life. These advances have resulted in meaningful improvements in the ability of patients to fight their cancers while minimizing the intrusions that cancer treatment can impose on them and their loved ones.”

Most importantly, the overall survival rate of patients treated with radiation seeds compared favorably to that of patients who had undergone whole-brain radiation therapy. Median survival for patients treated with tumor removal and radiation seeds was 14 months, while 27 percent survived two years. Previous studies have reported the median survival rate for patients who underwent tumor removal and WBRT at 10 to 12 months.

“The important conclusion is that patients with a single metastatic tumor of the brain that is surgically accessible can avoid the risks of whole-brain radiation and can be effectively treated with surgery, radiation seeds, and watchful followup every three months,” Dr. Warnick said.

More than 100,000 cases of metastatic brain cancer occur in the United States each year. Brain metastasis, which represents the spread of cancer from another area of the body, is the most common type of adult brain tumor. It occurs in 15 to 30 percent of patients with cancer. About 20 to 30 percent of patients who develop brain metastasis will suffer a single lesion.
Additional co-authors of the study are Christopher McPherson, M.D., Director of the Division of Surgical Neuro-Oncology at UC, and Michael Petr, M.D., a former resident in the UC Department of Neurosurgery.

The UC Brain Tumor Center, under the direction of Dr. Warnick, treats hundreds of patients from the Greater Cincinnati region and beyond each year. The multidisciplinary center, which includes specialists in neurosurgery, radiology, radiation oncology, otolaryngology, internal medicine and physical medicine and rehabilitation, is committed to evidence-based medicine, compassionate care, research, and the utilization of emerging therapies and technologies.

The UC Neuroscience Institute, a regional center of excellence, is dedicated to patient care, research, education, and the development of new treatments for stroke, brain and spinal tumors, epilepsy, traumatic brain and spinal injury, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, disorders of the senses (swallowing, voice, hearing, pain, taste and smell), and psychiatric conditions (bipolar disorder, schizophrenia and depression).

The Mayfield Clinic is recognized as one of the nation's leading physician organizations for clinical care, education, and research of the spine and brain. Supported by 20 neurosurgeons, three neurointensivists, an interventional radiologist, and a pain specialist, the Clinic treats 20,000 patients from 35 states and 13 countries in a typical year. Mayfield's physicians have pioneered surgical procedures and instrumentation that have revolutionized the medical art of neurosurgery for brain tumors and neurovascular diseases and disorders.

# # #